June 2018 - 20 articles
Significant progress has been made in the treatment of stage IV non-small-cell lung cancer (NSCLC); however, the prognosis of patients with brain metastases remains poor. Resection and radiation therapy remain standard options. This issue is an impor...
Although screening mammography has delivered many benefits since its introduction in Canada in 1988, questions about perceived harms warrant an up-to-date review. To help oncologists and physicians provide optimal patient recommendations, the literat...
Early-stage hormone receptor–positive breast cancer is the most common subtype and stage presenting in countries with organized screening programs. Standard clinical and pathologic factors are routinely used to support prognosis and decisions about a...
Estrogen receptor modulators and estrogen deprivation have become standards of care for hormone receptor– positive metastatic breast cancer. However, after traditional first-line endocrine monotherapy treatment, the disease typically progresses despi...
Triple-negative breast cancer constitutes a heterogeneous group of malignancies that are often aggressive and associated with a poor prognosis. Molecular characterization, while not a standard of care, can further subtype triple-negative breast cance...
Background: A number of clinical practice guidelines (CPGS) concerning breast cancer (BCA) screening and management are available. Here, we review the strengths and weaknesses of CPGS from various professional organizations and consensus groups with...
Background: Life expectancy for women with metastatic breast cancer has improved since the early 2000s, in part because of the introduction of novel therapies, including chemotherapy, hormonal therapy, and targeted agents. However, those treatments c...
Cancer therapy has evolved significantly with increased adoption of biologic agents (“biologics”). That evolution is especially true for HER2 (human epidermal growth factor receptor-2)–positive breast cancer with the introduction of trastuzumab, a mo...
Endocrine therapy, a major modality in the treatment of hormone receptor (HR)–positive breast cancer (BCA), has improved outcomes in metastatic and nonmetastatic disease. However, a limiting factor to the use of endocrine therapy in BCA is resistance...
Tumours with sensitizing mutations in the EGFR gene constitute a distinct molecular subgroup of non-small-cell lung cancers (NSCLCS) that benefit from precision medicine. First- and second-generation epidermal growth factor receptor (EGFR) tyrosine k...
of 2
Get Alerted
Add your email address to receive forthcoming issues of this journal.
